CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has granted equity awards to 18 new non-executive employees as part of its 2025 Inducement Plan, reinforcing the biopharmaceutical company’s strategy to attract and retain top talent amid its ongoing commercial expansion.
The awards, approved November 1 by Madrigal’s independent Compensation Committee, were issued under Nasdaq Listing Rule 5635(c)(4), which allows equity grants outside of shareholder-approved plans as an employment incentive. In total, the new hires received 7,301 time-based restricted stock units that vest in four equal installments over four years, contingent upon continued employment.
The equity inducements are designed to align employee interests with long-term shareholder value as Madrigal continues advancing its breakthrough liver disease treatment, Rezdiffra (resmetirom). The once-daily oral therapy is the first and only medication approved by both the U.S. Food and Drug Administration and the European Commission for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis (F2 to F3).
Madrigal is also conducting a Phase 3 outcomes trial evaluating Rezdiffra in patients with compensated MASH cirrhosis (F4c), a key step in expanding the drug’s potential indications.
By linking equity to employee tenure and performance, Madrigal aims to strengthen its workforce during a critical phase of growth in the rapidly evolving MASH therapeutic market.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.